According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is $2.09 Billion USD. In 2023 the company made a revenue of $1.82 Billion USD an increase over the revenue in the year 2022 that were of $1.03 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.